GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PRTG
Portage Biotech is a unique biotech company that invests in a portfolio of promising oncology developments. Its stock price represents a diversified bet on the success of multiple clinical programs, reducing risk compared to a single-product company.
Share prices of companies in the market segment - General oncology therapy
Portage Biotech is an oncology company that invests in and develops a portfolio of promising cancer drug candidates. We've categorized it as a "General Oncology" company. The chart below shows how investors value companies with a diversified approach to drug development.
Broad Market Index - GURU.Markets
Portage Biotech is an oncology company that invests in and develops a portfolio of promising cancer drug candidates. We've categorized it as a "General Oncology" company. The chart below shows how investors value companies with a diversified approach to drug development.
Change in the price of a company, segment, and market as a whole per day
PRTG - Daily change in the company's share price PRTG
Portage Biotech Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures its sensitivity to news about clinical trials of its immuno-oncology drugs.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Portage Biotech is a biopharmaceutical company with a diversified portfolio of early-stage oncology drugs. This model is aimed at mitigating risks in the volatile biotech sector. The chart below reflects average fluctuations in this industry, providing context for evaluating PRTG stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Portage Biotech is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PRTG
Portage Biotech Inc.'s year-over-year performance tells the story of its unique oncology investing model. Its market cap change over the past 12 months reflects the progress of its subsidiaries, each developing its own drugs. The success of any one of these companies can drive growth for the entire company.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Portage, as a biotech company with a diversified portfolio, is a unique player. Its performance reflects the success of its various subsidiaries. Compared to the sector, its model diversifies risks but may lack the growth potential of companies with a single, successful blockbuster.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Portage Biotech is a biotech company whose value is locked into its cancer drug pipeline. Its shares move in sync with clinical trial news. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PRTG
Portage is a biopharmaceutical company with a diversified portfolio. Its monthly performance reflects the combined impact of news across its many subsidiaries and clinical programs. Progress in any one of these programs can impact its valuation.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Portage Biotech is a biotech company that invests in and develops a portfolio of promising immuno-oncology drugs at various stages of development. The chart below shows the overall dynamics of the oncology sector, reflecting a business model based on risk diversification in drug development.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Portage Biotech move in sync with it, or do its R&D developments create a completely independent story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PRTG
Portage Biotech, an oncology company with a diversified portfolio, shares reflect its strategy on a weekly basis. Price movements reflect news from clinical trials of multiple drugs, reducing reliance on a single candidate.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Portage Biotech operates as an incubator, investing in a portfolio of oncology developments. The chart will help you compare its weekly performance with the sector and understand whether its diversified approach protects it from individual project failures or whether it moves in line with overall biotech trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Portage Biotech is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Portage Biotech is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
PRTG - Market capitalization of the company PRTG
Portage Biotech's market capitalization tells the story of a company with a unique business model: it invests in and develops a portfolio of promising oncology drugs. Its volatile chart is a tale of diversified bets in biotech, where the success of one program can offset the failure of others.
PRTG - Share of the company's market capitalization PRTG within the market segment - General oncology therapy
Portage Biotech uses a unique model for investing in and developing oncology drugs. Its share of the biotech sector's market capitalization reflects the market valuation of its portfolio. The chart shows how its weighting changes based on the successes and failures of its various investments.
Market capitalization of the market segment - General oncology therapy
Portage Biotech is a biotech company with a diversified portfolio of oncology developments. The chart below shows the overall market capitalization of this sector. Its dynamics provide a backdrop against which Portage is attempting to mitigate risk by investing in several promising areas simultaneously.
Market capitalization of all companies included in a broad market index - GURU.Markets
Portage Biotech is a biotech company with a diversified portfolio of oncology developments. Its market cap is essentially a bet on several different scientific approaches to cancer treatment. Its performance on the overall chart reflects how investors view its strategy for diversifying risks in the biotech world.
Book value capitalization of the company, segment and market as a whole
PRTG - Book value capitalization of the company PRTG
Portage Biotech's balance sheet represents the capital it invests in a portfolio of promising early-stage oncology developments. The book value reflects the underlying financial foundation of this venture-based biotech model. How has the valuation of this diversified portfolio changed? The chart below shows its dynamics.
PRTG - Share of the company's book capitalization PRTG within the market segment - General oncology therapy
Portage Biotech is a biopharmaceutical company investing in oncology drug development through its subsidiaries. The chart shows the total share of their R&D assets, reflecting the physical foundation of its diversified portfolio.
Market segment balance sheet capitalization - General oncology therapy
Portage, a biopharmaceutical company, has a lightweight model. It focuses on managing its development portfolio, often outsourcing lab research. The biotech sector's BCap_Seg chart serves as a backdrop to its strategy of being flexible and fast.
Book value of all companies included in the broad market index - GURU.Markets
Portage Biotech's balance sheet isn't a single development, but a portfolio of investments in several promising oncology drugs at various stages of research. The company's assets represent its diversified scientific capital. The chart shows how this "venture" model compares in terms of assets compared to other biotech companies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PRTG
Portage Biotech operates as an incubator for oncology startups. Its balance sheet consists of investments in portfolio companies. Market capitalization is the combined hope of investors for the success of at least one of these developments. The MvsBCap_Co chart reflects the risky but potentially highly profitable venture capital model in biotech.
Market to book capitalization ratio in a market segment - General oncology therapy
Portage Biotech has a unique business model: it invests in and develops a portfolio of several oncology biotech companies. Its valuation on the chart reflects the combined potential of these diverse approaches to cancer treatment.
Market to book capitalization ratio for the market as a whole
Portage Biotech Inc., an oncology company, invests in a portfolio of various developments. Its market valuation is the investors' bet that at least one of the projects will succeed. This chart shows how much expectations for the biotech sector as a whole outpace the overall market sentiment.
Debts of the company, segment and market as a whole
PRTG - Company debts PRTG
Portage Biotech, a company with a unique model that invests in and develops promising early-stage oncology drugs, uses capital to finance its portfolio. This chart shows how the company allocates resources among several high-risk projects, hoping that one or more will be successful.
Market segment debts - General oncology therapy
Portage Biotech is a biotech company with a unique model: it acquires and develops a portfolio of oncology assets. This chart shows that the company, like other R&D-stage players in the sector, funds its diverse projects primarily with equity rather than debt, managing risk across the entire portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PRTG
Portage Biotech is a biotech company with a unique model: it identifies and develops promising oncology drugs, creating subsidiaries for them. This chart shows how the holding company uses debt to finance its portfolio of risky but potentially breakthrough projects, reflecting its overall financial strategy.
Market segment debt to market segment book capitalization - General oncology therapy
Portage Biotech has a unique business model: it identifies and acquires promising early-stage oncology developments and advances them to clinical trials. The chart shows how aggressively the biotech sector uses debt, providing context for assessing how Portage finances its portfolio of risky but potentially valuable assets.
Debt to book value of all companies in the market
Portage Biotech Inc. takes a portfolio approach to oncology development, investing in multiple projects simultaneously. This chart, reflecting the overall market leverage, provides context for assessing its unique model. It helps understand how the company manages risk and financing for its diversified biotech portfolio.
P/E of the company, segment and market as a whole
P/E - PRTG
Portage Biotech is a biopharmaceutical company that acquires and develops promising immuno-oncology drugs. This chart shows how the market evaluates its portfolio strategy. This evaluation depends on the clinical success of its various candidates and its ability to identify new breakthrough technologies.
P/E of the market segment - General oncology therapy
Immuno-oncology, the focus of Portage Biotech, is at the cutting edge of science. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that Portage, with its incubator model for new oncology drugs, is valued as a diversified portfolio of risky but potentially highly valuable scientific ideas.
P/E of the market as a whole
Portage Biotech is a biotech company with a portfolio approach. It invests in several early-stage projects, diversifying risks. Its valuation reflects the overall potential of its portfolio. It is not tied to the overall economic trends shown in this chart, but rather depends on research data from several programs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PRTG
This chart for Portage Biotech Inc., a biopharmaceutical company with a diversified immuno-oncology pipeline, shows market expectations for its clinical programs. It reflects investors' collective belief in the potential of several of its drug candidates.
%20P%2FE%20PRTG&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PRTG&v=1772544834305 "Chart of the company's future (projected) P/E PRTG")
Future (projected) P/E of the market segment - General oncology therapy
Portage Biotech is a biotech company that discovers and develops promising immuno-oncology drugs. Its model involves creating subsidiaries for each asset. The chart shows forecasts for the oncology sector. This helps assess how the market views Portage's unique "hub-and-spoke" model and the risks associated with its diversified yet early-stage portfolio.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772544834351 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Portage Biotech Inc. is a biotech company with a diversified portfolio of oncology developments. This approach reduces the risks associated with the failure of a single drug. This graph of overall risk appetite shows how willing investors are to invest in biotech companies that employ a portfolio approach to innovation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772544834357 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PRTG
Portage Biotech is an oncology company that acquires and develops promising early-stage drugs. Its business model is to manage a portfolio of biotech assets. Financial results reflect research expenditures across the entire portfolio. This chart illustrates the financial implications of a venture-based approach to drug development.
Profit of companies in the market segment - General oncology therapy
Portage Biotech is a biotech company that invests in and develops a portfolio of promising oncology drugs. This graph, which reflects the sector's profitability, demonstrates the risky yet potentially rewarding nature of cancer drug discovery. Their model allows them to diversify risk by simultaneously developing multiple drugs with different mechanisms of action.
Overall market profit
Portage Biotech is a biotech company that invests in and manages the development of new cancer treatments. Its portfolio approach diversifies the risks associated with individual drug failures. Success depends on clinical trial results. This total return chart reflects the investment climate, which is important for funding the entire biotech sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PRTG
Portage Biotech is a biotech company that invests in the development of innovative oncology therapeutics, using a diversified portfolio approach to mitigate risk. This chart reflects analysts' speculative expectations for the success of its portfolio companies and their ability to advance candidates through clinical trials.
%20profit%20of%20the%20company%20PRTG&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PRTG&v=1772544834581 "Graph of future (projected) profit of the company PRTG")
Future (predicted) profit of companies in the market segment - General oncology therapy
Portage Biotech is a biotech company that invests in promising early-stage oncology developments and advances them through clinical trials. Its model is based on portfolio management. This chart for the oncology sector reflects overall investor interest in new cancer treatments, which influences Portage's portfolio valuation.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772544834619 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Portage Biotech is an oncology company investing in and developing new cancer treatments. Its success depends on the right choice of research projects. The overall profit forecast shown in this chart influences the overall biotech investment climate and the valuation of the assets it invests in.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772544834633 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PRTG
Portage Biotech is a company that acquires and develops promising early-stage oncology drugs. The chart shows how investors value its unique business model. This valuation reflects management's belief in its ability to discover and develop innovative cancer treatments while building a diversified portfolio.
P/S market segment - General oncology therapy
Portage Biotech Inc. operates on a model of discovering and developing promising oncology drugs, acquiring them at an early stage. Its valuation is based on the potential of a diversified portfolio of assets. This chart, which shows the average valuation in the biotech industry, helps understand how investors value this strategy compared to companies with a single lead pipeline.
P/S of the market as a whole
Portage Biotech is a hub-and-spoke biotech company, acquiring and developing promising oncology drugs through a portfolio of subsidiaries. This chart, reflecting revenue estimates for its actual businesses, highlights how Portage's value is a bet on its ability to effectively manage a portfolio of risky oncology assets.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PRTG
Portage Biotech is a biotech company that invests in and develops a portfolio of early-stage oncology drugs. Its model is risk diversification. This chart reflects the combined investor expectations for the success of several of its programs, not a single molecule.
%20P%2FS%20PRTG&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PRTG&v=1772544834671 "The graph of the company's future (projected) P/S PRTG")
Future (projected) P/S of the market segment - General oncology therapy
Portage Biotech Inc. is a clinical-stage immuno-oncology company developing a pipeline of novel drugs that target various immune system mechanisms to fight cancer. This chart reflects average revenue expectations in the oncology sector and provides insight into how the market views Portage Biotech's diversified approach.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772544834733 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Portage Biotech is a biopharmaceutical company that invests in and manages the development of innovative oncology drugs. This chart illustrates general market expectations. The company's portfolio approach allows it to diversify drug development risks and participate in multiple potential breakthroughs in cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772544834749 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PRTG
This chart illustrates the revenue of Portage Biotech, a clinical-stage company developing immuno-oncology drugs. Its revenue is generated not from product sales but from partnership fees and technology licensing, reflecting the progress of its research and development pipeline.
Sales of companies in the market segment - General oncology therapy
Portage Biotech is an oncology company investing in the development of a broad portfolio of immunotherapy drugs through its subsidiaries. This chart reflects the dynamics of the biotech sector. Portage's diversified approach allows it to mitigate the risks associated with drug development and participate in several promising areas of cancer research.
Overall market sales
Portage Biotech is a biotech company investing in oncology drug development. Its success depends on the clinical trial results of its portfolio companies. The overall economic situation, shown in this chart, influences the availability of capital for funding risky biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PRTG
Portage Biotech is an oncology company with a diversified immunotherapy pipeline. Future revenue depends on the success of several clinical programs simultaneously. The chart reflects aggregate analyst expectations for its entire pipeline of potential drugs.
%20sales%20of%20the%20company%20PRTG&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PRTG&v=1772544834939 "Schedule of future (projected) sales of the company PRTG")
Future (projected) sales of companies in the market segment - General oncology therapy
Portage Biotech is a biopharmaceutical company with a unique model that identifies and develops promising oncology drugs at early stages, advancing them to clinical trials. This chart shows the forecast for the entire oncology market, where Portage's innovative approach to asset development could lead to the creation of new treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772544834979 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Portage Biotech is a biotech company investing in and developing a portfolio of oncology drugs at various stages of development. Its value is the sum of its assets' potential. This graph, reflecting the overall sentiment in the biotech sector, influences the valuation of its portfolio companies and its ability to raise capital for further development.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772544834992 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PRTG
Portage Biotech is a biotech company with a unique model: it discovers and invests in promising early-stage oncology developments. Its financial results reflect both R&D expenditures at its portfolio companies and potential revenue from their sale or licensing. This chart illustrates the financial side of a venture-based approach to cancer drug development.
Market segment marginality - General oncology therapy
Portage Biotech is a biopharmaceutical company that invests in and develops a portfolio of innovative oncology drugs through its subsidiaries. Profitability depends on the success of clinical trials and strategic partnerships. This chart reflects the consolidated operating expenses of their diversified approach to cancer drug development.
Market marginality as a whole
Portage Biotech invests in and develops a portfolio of promising early-stage oncology drugs. Their model is focused on discovering and advancing innovative therapies. This overall profitability curve is irrelevant to them. Their success depends on their ability to select the right assets and the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company PRTG
Portage Biotech uses a unique model, investing in several early-stage biotech companies. Its in-house staff is minimal and consists of experienced managers. This chart demonstrates a capital-efficient structure, with the bulk of the work being done within its portfolio companies.
Share of the company's employees PRTG within the market segment - General oncology therapy
Portage Biotech uses a unique business model for oncology drug development, managing a portfolio of assets through its subsidiaries. This chart reflects its lean structure. It shows how a small, central team can effectively manage the development of multiple promising drugs while optimizing costs.
Number of employees in the market segment - General oncology therapy
Portage Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology drugs. This chart shows the dynamics of employment in the oncology sector. The growth in the number of scientists and clinicians reflects the company's efforts to advance its pipeline through clinical trials to develop new cancer treatments.
Number of employees in the market as a whole
Portage Biotech is a biotechnology company investing in oncology drug development. Its business model is based on identifying and developing promising scientific ideas. Overall economic stability, reflected in this chart, influences the availability of capital for funding portfolio companies and the interest of major pharmaceutical partners.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PRTG (PRTG)
Portage Biotech is a biotech company operating under the incubator model: it discovers and develops promising oncology drugs through a portfolio of subsidiaries. Portage itself has a minimal staff (management and research). The graph shows that the cost per employee is very high, as it reflects the combined value of the entire R&D portfolio managed by this small team.
%20of%20the%20company%20PRTG%20(PRTG)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PRTG-PRTG&v=1772544835417 "Chart of market capitalization per employee (in thousands of dollars) of the company PRTG (PRTG)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Portage Biotech uses a unique business model to invest in and develop promising oncology drugs. The company identifies and funds early-stage developments, mitigating risk. This chart shows how the market evaluates the effectiveness of this investment strategy and the value of its asset portfolio based on its small management team.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772544835427 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Portage Biotech is a biotech company investing in and developing a portfolio of oncology drugs. The chart demonstrates the valuation of its unique business model. It reflects how a small team of experts manages a portfolio of various assets at various stages, diversifying drug development risks.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772544835548 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PRTG (PRTG)
Portage Biotech is a biotech company with a portfolio model. They discover and acquire promising oncology drugs at an early stage and fund their clinical trials. This is an R&D business. This chart shows the company's capital burn: the amount the company spends on each scientist and manager managing this portfolio.
%20Chart%20PRTG%20(PRTG)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PRTG-PRTG&v=1772544835609 "Company Profit Per Employee (in thousands of dollars) Chart PRTG (PRTG)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Portage Biotech is a biotech company with a unique model. They don't conduct R&D themselves, but rather discover and invest in promising oncology drugs, creating spinoffs for them. This metric reflects the effectiveness of this venture-based model, managed by a small team.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772544835704 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Portage Biotech is a clinical-stage biotech company specializing in cancer immunotherapy. It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss per team of scientists developing the new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772544835734 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PRTG (PRTG)
Portage Biotech is a biopharmaceutical company investing in and developing a portfolio of oncology drugs. This chart reflects the performance of its investment model. Revenue per employee growth will depend on the success of clinical trials of its portfolio companies and subsequent partnerships or licensing.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PRTG-PRTG&v=1772544835906 "Sales chart per company employee PRTG (PRTG)")
Sales per employee in the market segment - General oncology therapy
Portage Biotech (PRTG) is a biotech company focused on developing immuno-oncology drugs. While in the clinical stage, their revenue (if any) comes from partnerships. This chart shows how productive their R&D team is in monetizing their developments per scientist.
Sales per employee for the market as a whole
Portage Biotech (PRTG) is a clinical-stage biotech company focused on developing immunotherapies for cancer treatment. The company currently has no approved products on the market. This graph illustrates a classic R&D scenario: a team of highly qualified scientists and physicians working on developing future drugs, consuming investment capital.
Short shares by company, segment and market as a whole
Shares shorted by company PRTG (PRTG)
Portage Biotech is a biotech holding company that invests in and manages a portfolio of various companies developing cancer drugs. The bearish sentiment shown in this chart reflects investors' bets that this complex "fund-in-company" model is ineffective and that none of its many assets will succeed.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PRTG-PRTG&v=1772544836158 "Short Shares Chart for the Company PRTG (PRTG)")
Shares shorted by market segment - General oncology therapy
Portage Biotech (PRTG) operates as an incubator, managing a portfolio of assets in the immuno-oncology field. The company identifies and develops new approaches to cancer treatment. This indicator measures the overall volume of bearish bets on the entire oncology biotech sector. It reflects the market's collective skepticism regarding the high costs and low probability of success of clinical trials in this complex field.
Shares shorted by the overall market
Portage Biotech is a biotech company focused on oncology. It's a classic R&D story. This chart measures the overall level of fear in the market. When it's high, investors are unwilling to fund multi-year clinical trials. They see "another unprofitable company" and sell it, fearing the "cash" will run out before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PRTG (PRTG)
Portage Biotech is a holding company investing in a portfolio of biotech startups working in oncology. Its price is a bet on the success of its portfolio companies. This indicator measures how the market values the portfolio, showing "overheated" (above 70) for successful trials or "oversold" (below 30) for failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PRTG-PRTG&v=1772544836241 "RSI 14 indicator chart for the company's stock PRTG (PRTG)")
RSI 14 Market Segment - General oncology therapy
Portage Biotech is a clinical-stage biotech with a diversified approach. They are developing a portfolio of immuno-oncology drugs targeting various cancer mechanisms. This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Portage Biotech (PRTG) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRTG (PRTG)
Portage Biotech (PRTG) is a clinical-stage immuno-oncology company developing a pipeline of cancer treatments. This chart shows the average target price. It reflects analysts' speculative assessment of this diversified scientific platform and its chances of success in early clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRTG-PRTG&v=1772544836321 "A chart showing analyst consensus forecasts for the expected stock price. PRTG (PRTG)")
The difference between the consensus estimate and the actual stock price PRTG (PRTG)
Portage (PRTG) is an oncology incubator. The company isn't pursuing a single drug, but rather invests in and develops a portfolio of several biotech startups in immuno-oncology. This chart shows how the current share price differs from its "fair" value. It reflects the "aggregate" analyst valuation of this risky R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRTG-PRTG&v=1772544836339 "A chart showing the difference between the consensus forecast and the actual stock price. PRTG (PRTG)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Portage Biotech is an "R&D incubator." The company doesn't discover drugs itself, but invests in a portfolio of junior biotechs specializing in immuno-oncology. This chart displays analysts' overall expectations for the *entire* oncology sector. It shows whether experts believe in this "portfolio" R&D model.
Analysts' consensus forecast for the overall market share price
Portage Biotech (PRTG) is a biotech incubator. They don't conduct R&D themselves, but rather manage a portfolio of subsidiaries, each of which develops its own drug (primarily for cancer). This chart shows the overall risk appetite of PRTG. It reflects the market's willingness to invest in complex holding structures in the riskiest sector.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PRTG
Portage is a biotech incubator. They don't have a single selling point; their business is discovery, acquisition (M&A), and development of a pipeline of immuno-oncology drugs in R&D. This chart is a summary indicator of their R&D arbitrage. It reflects their ability to pick winners and their (very risky) progress in clinical trials.
AKIMA Market Segment Index - General oncology therapy
Portage Biotech (PRTG) is an accelerator in general oncology. Rather than inventing from scratch, they identify and accelerate (acquire) promising, early-stage R&D projects in immuno-oncology. This chart compares their composite index to the sector, showing how their venture-backed R&D model outperforms their competitors.
The AKIM Index for the overall market
Portage Biotech is a company investing in and developing a portfolio of immuno-oncology assets. It operates as an accelerator. This chart, reflecting the market average, provides a macro backdrop. It helps assess how the PRTG drug development model compares to overall economic trends in biotech.
